Effect of a Sugar Replacement on Blood Glucose Levels in Healthy Adults
Effect of the Replacement of Glycaemic Carbohydrates With Galacto-Oligosaccharide (GOS) Supplementation on Postprandial Glycaemic Response in Healthy Adults
University of Aberdeen
50 participants
Jan 17, 2025
INTERVENTIONAL
Summary
Diabetes and cardiovascular disease account for millions of deaths per year. One of the risk factors for both conditions is high blood sugar, particularly after eating (postprandial hyperglycaemia). Lowering blood sugar levels after a meal is expected to have a positive effect on preventing metabolic and cardiovascular diseases and improving the metabolic control of those who already suffer from these conditions. The aim of this study is to investigate the effect of Oligomate® (beta-galacto-oligosaccharide) on postprandial glycaemia when used as a partial replacement of glycaemic carbohydrates in a beverage in otherwise healthy volunteers. Volunteers will be given water with either Oligomate® or glucose (control) added. Blood samples will be collected at eight time points (two before drinking the beverage and six after) to measure glucose and insulin levels.
Eligibility
Inclusion Criteria6
- Healthy Men or Women
- Body Mass Index (BMI) 18.5-29.9 kg/m\^2
- Between 18 and 65 years of age
- Compliant (i.e., understands and is willing, able, and likely to comply with the experimental procedure and safety guidelines)
- Able to provide informed consent
- Premenopausal women must have a regular cycle or be on hormonal contraception.
Exclusion Criteria14
- Diabetes mellitus (all types including gestational diabetes)
- HbA1c result over the study limit \[healthy range of between 4% and 5.9%\]
- Endocrine disease (e.g., Cushing's syndrome)
- Any food allergy or intolerance, or following Vegan diet
- Medications that increase blood glucose (e.g., steroids, protease inhibitors, antipsychotics, antihypertensives, statins, diuretics, nicotinic acid, etc.)
- Medications that lower glycemia (e.g., anti-hyperglycaemics, insulin, beta- blockers, etc.)
- Medication affecting glucose regulation, appetite, and/or digestion/absorption of nutrients, antibiotics
- Major medical or surgical event requiring hospitalization in the previous 3 months
- Pregnant or lactating
- Participation in another clinical/supplementation trial or actively trying to reduce body weight
- Unable to comply with experimental procedures and safety guidelines
- Unable to give consent
- Smokers
- Travel during the study period
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
24.0 g Oligomate® in 100 mL water
17.8 g glucose in 100 mL water
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06714552